Key facts
| Recalling firm | Sterling Pharmaceutical Services LLC |
|---|---|
| Manufacturer | Reliable 1 Laboritories LLC |
| Brand name | SODIUM CHLORIDE HYPERTONICITY OPHTHALMIC SOLUTION, 5% |
| Product description | Reliable -1 Laboratories, Sodium Chloride Hypertonicity Ophthalmic Solution, 5%, Sterile, 0.5 FL OZ (15 mL) bottles, Distributed by: Reliable-1 Laboratories LLC, Valley Stream, NY, 11580, NDC 69618-077-55. |
| Classification | Class II |
| Recall number | D-0856-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Lack of Assurance of Sterility |
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Reliable -1 Laboratories, Sodium Chloride Hypertonicity Ophthalmic Solution, 5%, Sterile, 0.5 FL OZ (15 mL) bottles, Distributed by: Reliable-1 Laboratories LLC, Valley Stream, NY, 11580, NDC 69618-077-55. should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Sterling Pharmaceutical Services LLC. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Sterling Pharmaceutical Services LLC should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Sterling Pharmaceutical Services LLC directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
Sterling Pharmaceutical Services LLC’s FDA history
Argus HQ has recorded 9 total FDA actions tied to Sterling Pharmaceutical Services LLC: 0 warning letters, 9 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Who should I contact about this recall?
- Contact Sterling Pharmaceutical Services LLC directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
- Has Sterling Pharmaceutical Services LLC had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 9 total FDA actions tied to Sterling Pharmaceutical Services LLC, including 9 recalls and 0 warning letters.
- What is the FDA recall number for this event?
- FDA recall number D-0856-2026.
- What is the current status of this recall?
- Status as recorded by FDA: Ongoing.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Sterling Pharmaceutical Services LLC- Recall: Sterling Pharmaceutical Services LLC — Class II recall: AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%, Lubricant Eye Dro… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: Lubricant Eye Drops-Cameron Pharmaceuticals, Carboxymethylcellulose Sodium 0.5%,… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: Major LubriFresh P.M. Nighttime Ointment, Net wt. 0.125 oz. (3.5 g) tubes, Distr… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: Reliable-1 Laboratories Lubricating Tears, Sterile, 0.5 FL OZ (15 mL) bottles, D… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: TRP The Relief Products* Gentle Eyes Lubricant Eye Drops, Carboxymethylcellulose… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: Walgreens Lubricant Eye Drops, Carboxymethylcellulose sodium 0.5%, Lubricant Eye… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: Walgreens Lubricant Eye Drops, 0.5 FL OZ (15 mL) 1.0 FL OZ (30 mL) TOTAL, 2 coun… →
- Recall: Sterling Pharmaceutical Services LLC — Class II recall: AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5%, Lubricant Eye Dro… →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Class II Recall: SODIUM CHLORIDE HYPERTONICITY OPHTHALMIC SOLUTION, 5% by Sterling Pharmaceutical Services LLC — Recall Details. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/sterling-pharmaceutical-services-d-0856-2026-2026-09-30
"FDA Class II Recall: SODIUM CHLORIDE HYPERTONICITY OPHTHALMIC SOLUTION, 5% by Sterling Pharmaceutical Services LLC — Recall Details." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/sterling-pharmaceutical-services-d-0856-2026-2026-09-30.
Argus HQ Research. "FDA Class II Recall: SODIUM CHLORIDE HYPERTONICITY OPHTHALMIC SOLUTION, 5% by Sterling Pharmaceutical Services LLC — Recall Details." Digital Empire Holdings LLC. Accessed October 6, 2026. https://argushq.ai/recall/sterling-pharmaceutical-services-d-0856-2026-2026-09-30.
@misc{argushq_argushq_ai_recall_sterling_pharmaceutical_services_d_0856_2026_2026_09_30_2026,
title = {FDA Class II Recall: SODIUM CHLORIDE HYPERTONICITY OPHTHALMIC SOLUTION, 5% by Sterling Pharmaceutical Services LLC — Recall Details},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/sterling-pharmaceutical-services-d-0856-2026-2026-09-30},
note = {Accessed: October 6, 2026}
}Source: FDA.gov — Recalls ↗

